Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

OptimizeRx stock price, quote, forecast and news

OPRX
US68401U2042
A2JL4Z

Price

7.54
Today +/-
-0.24
Today %
-3.52 %
P

OptimizeRx stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the OptimizeRx stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the OptimizeRx stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the OptimizeRx stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze OptimizeRx's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

OptimizeRx Stock Price History

DateOptimizeRx Price
9/6/20247.54 undefined
9/5/20247.81 undefined
9/4/20247.53 undefined
9/3/20247.73 undefined
8/30/20248.31 undefined
8/29/20248.34 undefined
8/28/20248.17 undefined
8/27/20248.24 undefined
8/26/20248.41 undefined
8/23/20248.60 undefined
8/22/20248.31 undefined
8/21/20248.56 undefined
8/20/20248.43 undefined
8/19/20248.45 undefined
8/16/20248.34 undefined
8/15/20248.40 undefined
8/14/20248.36 undefined
8/13/20248.65 undefined
8/12/20248.34 undefined
8/9/20248.38 undefined

OptimizeRx Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into OptimizeRx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by OptimizeRx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects OptimizeRx’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of OptimizeRx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into OptimizeRx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing OptimizeRx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on OptimizeRx’s growth potential.

OptimizeRx Revenue, EBIT and net profit per share

DateOptimizeRx RevenueOptimizeRx EBITOptimizeRx Net Income
2026e128.52 M undefined274.69 M undefined16.07 M undefined
2025e115.98 M undefined-5.39 M undefined9.25 M undefined
2024e102.71 M undefined-7.16 M undefined6.64 M undefined
202371.52 M undefined-17.52 M undefined-17.57 M undefined
202262.45 M undefined-12.29 M undefined-11.44 M undefined
202161.29 M undefined360,000 undefined380,000 undefined
202043.31 M undefined-2.14 M undefined-2.21 M undefined
201924.6 M undefined-3.69 M undefined-3.14 M undefined
201821.21 M undefined180,000 undefined230,000 undefined
201712.13 M undefined-2.13 M undefined-2.1 M undefined
20167.75 M undefined-1.53 M undefined-1.54 M undefined
20157.22 M undefined-600,000 undefined-600,000 undefined
20146.5 M undefined-630,000 undefined-1.03 M undefined
20134.68 M undefined-270,000 undefined-270,000 undefined
20121.99 M undefined-450,000 undefined-450,000 undefined
20111.11 M undefined-1.45 M undefined-2.12 M undefined

OptimizeRx Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e
11467712212443616271102115128
--300.0050.0016.67-71.4375.0014.2979.1741.861.6414.5243.6612.7511.30
-100.0050.0050.0042.8657.1441.6757.1462.5055.8157.3861.2959.15---
0123345121524353842000
-10000-1-20-3-20-12-17-7-5274
-100.00-----14.29-16.67--12.50-4.65--19.35-23.94-6.86-4.35214.06
-200-10-1-20-3-20-11-176916
------100.00---33.33--54.55-135.2950.0077.78
4.644.744.87.468.199.99.8211.8613.3914.8317.6917.7817.12000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The OptimizeRx Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the OptimizeRx is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
10.31.13.48.275.18.918.910.584.774.113.85
0.50.61.52.12.83.13.46.57.417.924.822.236.25
0000000000001.04
0000000000000
0.10.1000.10.10.30.40.94.55.62.33.19
1.612.65.511.110.28.815.827.232.9115.198.654.33
00000200200100700600500400722.3
0000000000000
0000000000000
1.31.21.31.41.21.10.85.313.912.110.61349.4
00000003.714.714.714.722.778.36
0000000200100000568.05
1.31.21.31.41.21.319.329.427.425.836.1129.04
2.92.23.96.912.311.59.825.156.660.3140.9134.7183.37
                         
00000000000019.9
5.16.28.927.632.233.735.348.778.385.6166.6172.8190.79
-3.6-4.8-7-24-24.4-26-29.1-30.3-33.4-35.6-35.3-46.7-64.26
00-0.311.100000000
0000000000000
1.51.41.64.68.97.76.218.444.950131.3126.1126.55
0.90.60.80.80.80.40.50.40.50.60.61.52.23
0.100000.311.31.92.532.77.98
0.30.11.51.62.632.12.53.76.95.84.25.68
0000000000000
0000000000002
1.30.72.32.43.43.73.64.26.1109.48.417.88
00000000000034.23
0000000000004.34
00000002.45.70.30.20.10.37
00000002.45.70.30.20.138.94
1.30.72.32.43.43.73.66.611.810.39.68.556.82
2.82.13.9712.311.49.82556.760.3140.9134.6183.38
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of OptimizeRx provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand OptimizeRx's financial health and stability.

Assets

OptimizeRx's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that OptimizeRx must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of OptimizeRx after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into OptimizeRx's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
-200-10-1-20-3-20-11
000000001112
000000000000
0000000-2-1-9-73
10020015461131
000000000000
000000000000
001000-10-1-6010
00000000-1000
0000000-5-1000-58
0000000-5-800-57
000000000000
-100000000000
1002400822275-18
0002400822-173-18
----------4.00-1.00-
000000000000
00024-1-139-874-66
-0.75-0.620.98-0.180.52-0.66-1.520.7-3.25-6.430.2710.41
000000000000

OptimizeRx stock margins

The OptimizeRx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OptimizeRx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OptimizeRx.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the OptimizeRx's sales revenue. A higher gross margin percentage indicates that the OptimizeRx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the OptimizeRx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the OptimizeRx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the OptimizeRx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the OptimizeRx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the OptimizeRx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

OptimizeRx Margin History

OptimizeRx Gross marginOptimizeRx Profit marginOptimizeRx EBIT marginOptimizeRx Profit margin
2026e59.98 %213.73 %12.5 %
2025e59.98 %-4.64 %7.97 %
2024e59.98 %-6.97 %6.46 %
202359.98 %-24.5 %-24.56 %
202262.4 %-19.68 %-18.32 %
202158.15 %0.59 %0.62 %
202055.67 %-4.94 %-5.1 %
201962.76 %-15 %-12.76 %
201857.57 %0.85 %1.08 %
201749.05 %-17.56 %-17.31 %
201656 %-19.74 %-19.87 %
201549.86 %-8.31 %-8.31 %
201450.46 %-9.69 %-15.85 %
201360.26 %-5.77 %-5.77 %
201293.97 %-22.61 %-22.61 %
201159.98 %-130.63 %-190.99 %

OptimizeRx Stock Sales Revenue, EBIT, Earnings per Share

The OptimizeRx earnings per share therefore indicates how much revenue OptimizeRx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue OptimizeRx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates OptimizeRx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of OptimizeRx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating OptimizeRx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

OptimizeRx Revenue, EBIT and net profit per share

DateOptimizeRx Sales per ShareOptimizeRx EBIT per shareOptimizeRx Earnings per Share
2026e7.02 undefined0 undefined0.88 undefined
2025e6.33 undefined0 undefined0.5 undefined
2024e5.61 undefined0 undefined0.36 undefined
20234.18 undefined-1.02 undefined-1.03 undefined
20223.51 undefined-0.69 undefined-0.64 undefined
20213.46 undefined0.02 undefined0.02 undefined
20202.92 undefined-0.14 undefined-0.15 undefined
20191.84 undefined-0.28 undefined-0.23 undefined
20181.79 undefined0.02 undefined0.02 undefined
20171.24 undefined-0.22 undefined-0.21 undefined
20160.78 undefined-0.15 undefined-0.16 undefined
20150.88 undefined-0.07 undefined-0.07 undefined
20140.87 undefined-0.08 undefined-0.14 undefined
20130.97 undefined-0.06 undefined-0.06 undefined
20120.42 undefined-0.09 undefined-0.09 undefined
20110.24 undefined-0.31 undefined-0.46 undefined

OptimizeRx business model

The OPTIMIZERx Corporation is an emerging US company that is pursuing a revolutionary approach to solving challenges in healthcare. The company was founded in 2006 and is headquartered in Rochester, Michigan. OPTIMIZERx initially started as a provider of discount incentives to improve medication management. They later developed an innovative E-Prescribing platform to ensure the quick and secure delivery of medications to patients. Their business model focuses on providing scalable platforms and services to simplify and improve patient data management and communication. OPTIMIZERx offers products such as eCoupon, SampleMD, OptimizeRx Digital Therapeutic Support, and OptimizeRx 360. These platforms and services are sold to pharmaceutical companies, doctors, patients, and pharmacies to help reduce costs and optimize business processes. The company is divided into different categories including E-Prescribing, Patient-Centered Support, Point-of-Care Services, and Channel and Content Management. Overall, OPTIMIZERx aims to improve healthcare services through innovative technology and has achieved significant milestones such as a strong customer base and sustainable financial foundation. OptimizeRx is one of the most popular companies on Eulerpool.com.

OptimizeRx SWOT Analysis

Strengths

OPTIMIZERx Corp has several key strengths that contribute to its success in the market. Firstly, the company offers innovative and leading-edge technology solutions in the healthcare industry, providing a competitive advantage over its competitors. Additionally, OPTIMIZERx Corp has established strong strategic partnerships with hospitals, healthcare providers, and pharmaceutical companies, enabling it to expand its customer base and enhance its product offerings. Furthermore, the company has a dedicated and skilled workforce, fostering a culture of innovation, collaboration, and customer-centricity.

Weaknesses

Despite its strengths, OPTIMIZERx Corp also faces certain weaknesses that can hinder its growth and market position. One notable weakness is the dependence on a limited number of major clients for a significant portion of its revenue. This vulnerability exposes the company to potential risks, such as losing key clients or facing pricing pressures. Moreover, OPTIMIZERx Corp operates in a highly competitive market, where disruptive technologies and emerging companies pose a threat to its market share. The company needs to continuously invest in research and development to stay ahead of the competition.

Opportunities

OPTIMIZERx Corp has identified several opportunities that can drive future growth and profitability. The increasing adoption of digital healthcare solutions presents a promising opportunity for the company to expand its customer base and enhance its product portfolio. Moreover, the growing focus on personalized medicine and patient-centric care provides a platform for OPTIMIZERx Corp to develop tailored and targeted solutions that address specific patient needs. Additionally, the company can explore strategic partnerships with telehealth providers, electronic health record vendors, and other stakeholders in the healthcare ecosystem to leverage synergies and expand its market reach.

Threats

OPTIMIZERx Corp operates in an industry that faces various threats, which can impact its operations and financial performance. One significant threat is the strict regulatory environment in the healthcare sector. Compliance with existing and new regulations can increase the company's operational costs, hinder product development, and slow down market penetration. Additionally, the constantly evolving technology landscape poses a threat, as competitors can develop similar or superior solutions, challenging OPTIMIZERx Corp's market position. Economic downturns and budget constraints in the healthcare industry can also lead to reduced spending on technology solutions, affecting the company's revenue.

OptimizeRx Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

OptimizeRx historical P/E ratio, EBIT, and P/S ratio.

OptimizeRx shares outstanding

The number of shares was OptimizeRx in 2023 — This indicates how many shares 17.125 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue OptimizeRx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates OptimizeRx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of OptimizeRx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating OptimizeRx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

OptimizeRx Stock splits

In OptimizeRx's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for OptimizeRx.

OptimizeRx latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.07 0.02  (130.72 %)2024 Q2
3/31/2024-0.13 -0.11  (15.45 %)2024 Q1
12/31/20230.33 0.26  (-21.09 %)2023 Q4
9/30/20230.03 0.09  (252.94 %)2023 Q3
6/30/2023-0.02 -0.01  (54.34 %)2023 Q2
3/31/2023-0.08 -0.09  (-10.29 %)2023 Q1
12/31/20220.25 0.25  (1.5 %)2022 Q4
9/30/20220.04 0.07  (87.17 %)2022 Q3
6/30/20220.09 0.04  (-56.24 %)2022 Q2
3/31/2022-0.01 -0.01  (16.67 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the OptimizeRx stock

Eulerpool World ESG Rating (EESG©)

49/ 100

🌱 Environment

17

👫 Social

79

🏛️ Governance

52

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
5.82
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
5.82
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees42
Percentage of women in management—
Percentage of Asian employees5.5
Share of Asian management—
Percentage of Hispanic/Latino employees6.6
Hispano/Latino Management share—
Percentage of Black employees4.39
Black Management Share—
Percentage of white employees79.12
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

OptimizeRx list of shareholders

%
Name
Stocks
Change
Date
9.43 % First Light Asset Management, LLC1,727,298-758,74912/31/2023
7.56 % Weintraub (Michael)1,384,4671,384,46710/24/2023
5.76 % BlackRock Institutional Trust Company, N.A.1,054,31833,36312/31/2023
5.57 % The Vanguard Group, Inc.1,021,00228,41612/31/2023
5.18 % Divisadero Street Capital Management, LP949,550949,55012/31/2023
4.48 % AWM Investment Company, Inc.820,04237,47112/31/2023
4.05 % William Blair & Company, L.L.C. (Research)741,104-95,39412/31/2023
2.94 % Febbo (William J)538,14060,0004/15/2024
2.68 % Kennedy Capital Management LLC490,685-64,99012/31/2023
2.56 % G2 Investment Partners Management LLC468,12096,64612/31/2023
1
2
3
4
5
...
10

OptimizeRx Executives and Management Board

Ms. Marion Odence-Ford58
OptimizeRx Chief Compliance Officer, General Counsel
Compensation 2.48 M
Mr. Edward Stelmakh57
OptimizeRx Chief Financial Officer, Chief Operating Officer
Compensation 2.05 M
Mr. Stephen Silvestro45
OptimizeRx President, Chief Commercial Officer
Compensation 1.56 M
Mr. William Febbo54
OptimizeRx Chief Executive Officer, Director (since 2016)
Compensation 694,400
Mr. Patrick Spangler67
OptimizeRx Independent Director
Compensation 215,026
1
2
3

OptimizeRx Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Molina Healthcare Stock
Molina Healthcare
SupplierCustomer0,600,760,74-0,15-0,360,54
Medtronic Stock
Medtronic
SupplierCustomer0,490,690,690,130,620,68
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,420,74-0,51-0,79-0,49-0,05
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,330,66-0,66-0,62-0,68-0,20
Becton, Dickinson Stock
Becton, Dickinson
SupplierCustomer0,270,030,79-0,11-0,55-0,05
Sanofi Stock
Sanofi
SupplierCustomer0,200,59-0,49-0,80-0,74-0,13
Eli Lilly Stock
Eli Lilly
SupplierCustomer0,080,09-0,33-0,52-0,510,54
UnitedHealth Group Stock
UnitedHealth Group
SupplierCustomer0,040,660,40-0,28-0,590,44
Amgen Stock
Amgen
SupplierCustomer-0,01-0,55-0,14-0,67-0,71-0,58
Novartis Stock
Novartis
SupplierCustomer-0,100,52-0,87-0,84-0,42-0,12
1
2

Most common questions regarding OptimizeRx

What values and corporate philosophy does OptimizeRx represent?

Optimizerx Corp represents values of innovation, collaboration, and customer-centricity. With a strong corporate philosophy focused on improving patient access to life-saving therapies, Optimizerx Corp aims to enhance the healthcare ecosystem through its digital platform and strategic partnerships. Committed to delivering superior solutions and services, the company leverages cutting-edge technology and data-driven insights to empower patients, healthcare providers, and pharmaceutical manufacturers. Optimizerx Corp strives to optimize the healthcare experience, driving better outcomes, cost-savings, and improved patient adherence. As a trusted leader in the industry, Optimizerx Corp demonstrates a dedication to excellence, integrity, and creating value for its shareholders, healthcare partners, and the overall community.

In which countries and regions is OptimizeRx primarily present?

OPTIMIZERx Corp is primarily present in the United States.

What significant milestones has the company OptimizeRx achieved?

OPTIMIZERx Corp, a leading provider of digital health communication solutions, has achieved several significant milestones. The company experienced impressive revenue growth, surpassing $30 million in annual revenue in 2020. In addition, OPTIMIZERx Corp expanded its client base, forging partnerships with renowned pharmaceutical manufacturers, healthcare providers, and pharmacies. The company launched innovative solutions, such as its SampleRx platform, which allows patients to access cost-saving coupons and trial offers for prescription medications. OPTIMIZERx Corp also made strategic acquisitions, augmenting its capabilities and expanding its market reach. These milestones demonstrate the company's commitment to revolutionizing patient engagement and improving prescription affordability in the healthcare industry.

What is the history and background of the company OptimizeRx?

OPTIMIZERx Corp is a renowned digital health company that specializes in providing software solutions to streamline the pharmaceutical industry. Founded in 2006, OPTIMIZERx has established itself as a leader in the field, offering innovative platforms to enhance patient engagement and adherence. With a focus on improving communication between healthcare providers, pharmaceutical companies, and patients, OPTIMIZERx's solutions enable physicians to deliver cost-effective and personalized care. The company has consistently grown its presence by incorporating cutting-edge technologies and strategic partnerships, ensuring it stays at the forefront of the industry. OPTIMIZERx Corp's commitment to improving patient outcomes has made it a trusted name in the digital health sector.

Who are the main competitors of OptimizeRx in the market?

Some of the main competitors of OPTIMIZERx Corp in the market include Updox, Allscripts Healthcare Solutions, and NextGen Healthcare.

In which industries is OptimizeRx primarily active?

OPTIMIZERx Corp is primarily active in the healthcare and pharmaceutical industries.

What is the business model of OptimizeRx?

The business model of OPTIMIZERx Corp is focused on providing software solutions and technology platforms to the healthcare industry. The company offers a comprehensive suite of services, including electronic prescribing for healthcare providers, patient engagement and adherence tools, as well as financial assistance programs for patients to help them access and afford medication. OPTIMIZERx Corp's innovative technology enables pharmaceutical manufacturers to effectively engage with healthcare professionals and patients, improving patient outcomes and reducing healthcare costs. With its unique offerings and solutions, OPTIMIZERx Corp aims to optimize the connection between patients, healthcare providers, and pharmaceutical companies in the healthcare ecosystem.

What is the P/E ratio of OptimizeRx 2024?

The OptimizeRx P/E ratio is 19.45.

What is the P/S ratio of OptimizeRx 2024?

The OptimizeRx P/S ratio is 1.26.

What is the AlleAktien quality score of OptimizeRx?

The AlleAktien quality score for OptimizeRx is 6/10.

What is the revenue of OptimizeRx 2024?

The expected OptimizeRx revenue is 102.71 M USD.

How high is the profit of OptimizeRx 2024?

The expected OptimizeRx profit is 6.64 M USD.

What is the business model of OptimizeRx

The OPTIMIZERx Corp is a leading provider of digital solutions to improve patient communication, adherence, and access to medications. The company is headquartered in Rochester, Michigan and works with numerous pharmaceutical manufacturers, insurers, and pharmacies to optimize healthcare. One of OPTIMIZERx's main products is the Sample Fulfillment System (SFS), a paperless system for ordering and delivering medication samples to doctors. Doctors can access a wide range of medications, order samples, and effectively treat their patients through the system. The SFS is easy to use and provides doctors with a convenient way to receive medications and care for patients. OPTIMIZERx also offers a variety of patient communication solutions to improve compliance and adherence. The OPTIMIZERx portal is an online portal that allows patients to order and manage medications, as well as receive information about their medications and their side effects. The portal is user-friendly and easy to navigate, allowing patients to securely access their medical information. Another important area of OPTIMIZERx is supporting patients with coupons and discounts on prescription medications. OPTIMIZERx offers discount programs for a variety of medications to help patients manage the high costs of their medications. Similarly, OPTIMIZERx offers various options to assist patients in applying for discounts and ensuring they receive the best offer. In addition, OPTIMIZERx also provides communication solutions for pharmacies to improve information exchange and collaboration between pharmacies and doctors. The OPTIMIZERx eCoupon system allows pharmacies to pass on discounts and coupons directly to patients. In summary, the OPTIMIZERx Corp offers a wide range of digital solutions to improve patient communication, increase adherence and compliance, and facilitate access to medications. The company works closely with pharmaceutical manufacturers and other healthcare providers to optimize healthcare and provide the best possible support for patients.

What is the OptimizeRx dividend?

OptimizeRx pays a dividend of 0 USD distributed over payouts per year.

How often does OptimizeRx pay dividends?

The dividend cannot currently be calculated for OptimizeRx or the company does not pay out a dividend.

What is the OptimizeRx ISIN?

The ISIN of OptimizeRx is US68401U2042.

What is the OptimizeRx WKN?

The WKN of OptimizeRx is A2JL4Z.

What is the OptimizeRx ticker?

The ticker of OptimizeRx is OPRX.

How much dividend does OptimizeRx pay?

Over the past 12 months, OptimizeRx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OptimizeRx is expected to pay a dividend of 0 USD.

What is the dividend yield of OptimizeRx?

The current dividend yield of OptimizeRx is .

When does OptimizeRx pay dividends?

OptimizeRx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of OptimizeRx?

OptimizeRx paid dividends every year for the past 0 years.

What is the dividend of OptimizeRx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is OptimizeRx located?

OptimizeRx is assigned to the 'Health' sector.

Wann musste ich die Aktien von OptimizeRx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of OptimizeRx from 9/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.

When did OptimizeRx pay the last dividend?

The last dividend was paid out on 9/7/2024.

What was the dividend of OptimizeRx in the year 2023?

In the year 2023, OptimizeRx distributed 0 USD as dividends.

In which currency does OptimizeRx pay out the dividend?

The dividends of OptimizeRx are distributed in USD.

All fundamentals about OptimizeRx

Our stock analysis for OptimizeRx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OptimizeRx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.